alvespimycin Report issue

Small molecule Experimental
AACT ChEMBL DrugBank MeSH PubChem

Active Ingredient History

NOW
  • Now
17-Dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) is a chemical compound which is a semi-synthetic derivative of the antibiotic geldanamycin. It is being studied for the possibility of treating cancer.   Wikipedia

Chemistry

  • SMILES: CO[C@H]1C[C@H](C)CC2=C(NCCN(C)C)C(=O)C=C(NC(=O)\C(=C\C=C/[C@H](OC)[C@@H](OC(=O)N)\C(=C\[C@H](C)[C@H]1O)\C)\C)C2=O
  • InChIKey: KUFRQPKVAWMTJO-LMZWQJSESA-N
  • Mol. Mass: 616.76
  • ALogP: 1.91
  • ChEMBL Molecules:
    alvespimycin  
    alvespimycin hydrochloride  
More Chemistry

Pharmacology

Alternative names

17-desmethoxy-17-n,n-dimethylaminoethylamino-geldanamycin | 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin | 17-(dimethylaminoethylamino)-17-demethoxy-geldanamycin | 17-dimethylaminoethylamino-17-demethoxy-geldanamycin | 17dmag | 17-dmag | ((4e,6z,8s,9s,10e,12s,13r,14s,16r)-19-(2-dimethylaminoethylamino)-13-hydroxy-8,14-dimethoxy-4,10,12,16-tetramethyl-3,20,22-trioxo-2-azabicyclo(16.3.1)docosa-4,6,10,18,21-pentaen-9-yl) carbamate | alvespimycin | alvespimycin hcl | alvespimycin hydrochloride | bms-826476 | kos1022 | kos 1022 | kos-1022 | nsc707545 | nsc 707545

Organizations (7)

Research & Development (7)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Overview

  • Highest Phase: Phase 2
  • # of Trials: 7
  • # of Trial Organizations: 7

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue